AU2001239924A1 - Methods for selectively modulating survivin apoptosis pathways - Google Patents

Methods for selectively modulating survivin apoptosis pathways

Info

Publication number
AU2001239924A1
AU2001239924A1 AU2001239924A AU3992401A AU2001239924A1 AU 2001239924 A1 AU2001239924 A1 AU 2001239924A1 AU 2001239924 A AU2001239924 A AU 2001239924A AU 3992401 A AU3992401 A AU 3992401A AU 2001239924 A1 AU2001239924 A1 AU 2001239924A1
Authority
AU
Australia
Prior art keywords
methods
selectively modulating
apoptosis pathways
survivin apoptosis
modulating survivin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001239924A
Inventor
Dario C Altieri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of AU2001239924A1 publication Critical patent/AU2001239924A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2001239924A 2000-02-29 2001-02-28 Methods for selectively modulating survivin apoptosis pathways Abandoned AU2001239924A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09515514 2000-02-29
US09/515,514 US6509162B1 (en) 2000-02-29 2000-02-29 Methods for selectively modulating survivin apoptosis pathways
PCT/US2001/006341 WO2001064741A2 (en) 2000-02-29 2001-02-28 Methods for selectively modulating survivin apoptosis pathways

Publications (1)

Publication Number Publication Date
AU2001239924A1 true AU2001239924A1 (en) 2001-09-12

Family

ID=24051679

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001239924A Abandoned AU2001239924A1 (en) 2000-02-29 2001-02-28 Methods for selectively modulating survivin apoptosis pathways

Country Status (7)

Country Link
US (3) US6509162B1 (en)
EP (1) EP1259638A2 (en)
JP (1) JP2003525060A (en)
AU (1) AU2001239924A1 (en)
CA (1) CA2401607A1 (en)
MX (1) MXPA02008453A (en)
WO (1) WO2001064741A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE414149T1 (en) * 1996-11-20 2008-11-15 Univ Yale SURVIVIN, A PROTEIN THAT INHIBITS CELLULAR APOPTOSIS AND ITS MODULATION
DE60131498T8 (en) * 2000-02-02 2009-01-29 Anges Mg Inc., Toyonaka VIRUS COVENANT FOR GENERAL TRANSMISSION
EP1436311A4 (en) * 2001-09-24 2005-04-13 Hybridon Inc Antisense oligonucleotides and methods to induce tumor cell death
US7713738B2 (en) 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
BRPI0410886A (en) 2003-06-03 2006-07-04 Isis Pharmaceuticals Inc double stranded compound, pharmaceutical composition, pharmaceutically acceptable salt, methods of modifying human survivin-encoding nucleic acid, inhibiting suvivin expression in cells or tissues, and treating a condition associated with suvivin expression or overexpression, and single stranded RNA oligonucleotide
US20050019806A1 (en) * 2003-06-30 2005-01-27 Horvitz H. Robert Nucleic acids and polypeptides required for cell survival in the absence of Rb
EP1586654A1 (en) * 2004-04-15 2005-10-19 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Replication competent viruses capable of silencing virus inhibitory factor expression
US7342093B2 (en) * 2004-07-23 2008-03-11 University Of Massachusetts Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
EP1824975B9 (en) * 2004-11-09 2011-04-20 Santaris Pharma A/S Lna oligonucleotides and the treatment of cancer
AU2006206159A1 (en) * 2005-01-24 2006-07-27 Massachusetts Institute Of Technology Method for modeling cell signaling systems by means of bayesian networks
US20060276423A1 (en) * 2005-04-18 2006-12-07 Rachel Altura Survivin-directed RNA interference-compositions and methods
CN100424096C (en) * 2005-06-16 2008-10-08 华东理工大学 Survivin mutant containing HIV transduction structural area and its preparation method and uses
KR20100074177A (en) * 2007-09-10 2010-07-01 유니버시티 오브 매사추세츠 Mitochondria-targeted anti-tumour agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639458A (en) * 1987-03-20 1997-06-17 Regents Of The University Of California Class I MHC modulation of surface receptor activity
US6238875B1 (en) 1991-03-12 2001-05-29 The Scripps Research Institute Diagnostic methods useful in the characterization of lymphoproliferative disease characterized by increased EPR-1
ATE414149T1 (en) 1996-11-20 2008-11-15 Univ Yale SURVIVIN, A PROTEIN THAT INHIBITS CELLULAR APOPTOSIS AND ITS MODULATION
US6335194B1 (en) * 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
US6077709A (en) * 1998-09-29 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of Survivin expression

Also Published As

Publication number Publication date
US20110160278A1 (en) 2011-06-30
EP1259638A2 (en) 2002-11-27
US6509162B1 (en) 2003-01-21
MXPA02008453A (en) 2003-03-10
US20030143232A1 (en) 2003-07-31
US7553821B2 (en) 2009-06-30
WO2001064741A3 (en) 2002-05-02
JP2003525060A (en) 2003-08-26
WO2001064741A2 (en) 2001-09-07
CA2401607A1 (en) 2001-09-07

Similar Documents

Publication Publication Date Title
AU2003223687A1 (en) Combined ask/dpsk modulation system
AU2002217353A1 (en) Gabaa modulating neurosteroids
AU2002365825A1 (en) Modulation control
AU2001252612A1 (en) Ppargamma modulators
IL155090A0 (en) Methods for modulating bladder function
AU2001281126A1 (en) Lighting system for generating pre-determined beam-pattern
AU2001273639A1 (en) Aryl fused substituted 4-oxy-pyridines
AU2001239924A1 (en) Methods for selectively modulating survivin apoptosis pathways
AU3053102A (en) Methods for modulating angiogenesis
AU2001227140A1 (en) Method for inhibiting apoptosis under ischemic condition
AU2002353317A1 (en) A method for inducing apoptosis
AU2001230605A1 (en) Apoptosis inhibitor
AU2001265871A1 (en) Substituted sulfonylaminopyrimidines
AU2003224712A1 (en) Modulating angiogenesis
AU2001254731A1 (en) Substituted phenyluracils
AU2001271426A1 (en) Modulation of apoptosis
AU2001238125A1 (en) Hydristor control means
AU2001256742A1 (en) Crawler shoe
AU2001274101A1 (en) Wdm signal monitoring
AUPR604401A0 (en) Peptoid compounds
AU2001231725A1 (en) Device for emitting high-frequency signals
AU2000268585A1 (en) Phase modulator
AU2003271988A1 (en) Modulation of tgfbeta-like signalling pathways
AU2001256507A1 (en) Modulation
AU2003218662A1 (en) Modulation device